Dermata reports FY2024 cash burn; Phase 3 STAR-1 topline expected by end of March 2025

Dermata Therapeutics, Inc.

Cash and cash equivalents $3.2M as of Dec. 31, 2024, down from $7.4M; expects funding into Q3 2025 after $2.55M Jan. 2025 PIPE.
R&D expense $8.2M in 2024 vs $4.1M in 2023, driven by $4.9M increase in Phase 3 STAR-1 clinical trial costs.
Topline results from XYNGARI Phase 3 STAR-1 acne trial expected by end of March 2025.
Entered Clinical Trial Collaboration Agreement with Revance (Crown Laboratories) to study DMT410 with DAXXIFY for hyperhidrosis.
G&A expense $4.3M in 2024 vs $4.0M in 2023, primarily due to increased audit fees from auditor change.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.